Haga Hospital
- Address
- lock Available on a paid plan
Haga Hospital - Oncology and Hematology Research Center
Haga Hospital is a leading clinical research institution specializing in oncology and hematology, with extensive participation in advanced therapeutic trials for cancer and blood disorders. The center demonstrates particular expertise in targeted therapies, immunotherapy combinations, and novel treatment strategies for solid tumors and hematologic malignancies.
- Breast cancer research including hormone receptor-positive disease, triple-negative breast cancer, and HER2-targeted therapies with CDK4/6 inhibitors
- Multiple myeloma and plasma cell disorders, featuring bispecific antibodies, CAR-T therapies, and novel maintenance strategies
- Prostate cancer studies evaluating castration-resistant disease, targeted therapies, and hormonal treatment combinations
- Lymphoma trials including mantle cell lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia
The center actively participates in international multicenter trials investigating lung cancer, colorectal cancer, and rare conditions such as sickle cell disease and amyloidosis. Research extends beyond oncology to include cardiovascular disease, with trials examining antiplatelet therapy after stroke, heart failure management, and cardiogenic shock treatment. Additional focus areas include neurological disorders like multiple sclerosis, autoimmune conditions including systemic lupus erythematosus and ANCA vasculitis, and metabolic disorders such as obesity-related atrial fibrillation. The hospital's comprehensive clinical trial portfolio reflects a commitment to advancing precision medicine and improving patient outcomes across diverse therapeutic areas.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 26 therapeutic areas and 15 of 256 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 252 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 38 by active trials.
lock +37 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +28 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 271 other sites in The Netherlands
Therapeutic Area Benchmark — The Netherlands
Select a therapeutic area to compare against other sites in The Netherlands.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: The Netherlands
Market Share
Country: The Netherlands
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Haga Hospital
lock Showing 1 of 131 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (20321) An open-label, single arm, roll-over study to provide continued treatment with darolutamide in participants who were enrolled in previous Bayer sponsored studies | Bayer Consumer Care AG | Phase III | Not Recruiting | Oct 2020 | — |
IMP list
lock Showing 1 of 256 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dexamethasone | 10 | Unknown | 2016-02-19 | 2026-06-12 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.